Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2020-08-21 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于出售全资子公司股权暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of selling the equity of its wholly-owned subsidiary, which is described as a related party transaction. It details the approval dates, payment terms, completion of the first payment and equity transfer, and the impact on the company. The document is relatively short (1181 characters) and focuses on a transaction update rather than providing full financial statements or detailed financial analysis. It does not contain comprehensive financial data or results but rather informs about a capital transaction and its progress. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as equity sales.
2020-08-21 Chinese
关于公司向特定对象发行股票并在创业板上市发行注册环节反馈意见落实函的专项说明
Regulatory Filings
2020-08-20 Chinese
公司及中信证券股份有限公司关于发行注册环节反馈意见落实函之回复报告
Regulatory Filings Classification · 95% confidence The document is a detailed reply report from Betta Pharmaceuticals Co., Ltd. and CITIC Securities Co., Ltd. addressing feedback from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the company's stock issuance registration process. It discusses the company's accounting policies on capitalization of R&D expenses, compliance with accounting standards, and comparisons with peer companies. The document includes detailed explanations, tables, and verification statements from the sponsor and auditors. It is a formal response to regulatory feedback during the issuance registration process, not a financial report or earnings release. The presence of regulatory bodies, the nature of the content focusing on regulatory feedback and compliance, and the detailed reply format indicate this is a Regulatory Filing (RNS) rather than an Annual Report, Audit Report, or other categories. The document length (over 12,000 characters) and detailed content confirm it is not a brief announcement or certification letter, so it is not RPA or RNS fallback due to brevity or certification only. Therefore, the best classification is Regulatory Filings (RNS).
2020-08-20 Chinese
关于《发行注册环节反馈意见落实函》之反馈意见回复的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company regarding the response to feedback from the securities regulatory authority (China Securities Regulatory Commission) related to the issuance registration process. It mentions that the company has addressed the feedback and disclosed the detailed reply on an external website. The document is short (636 characters) and serves as a notification about the status of regulatory feedback and the company's compliance, not the actual report or financial data. It is an announcement related to regulatory filings and compliance rather than a full report or financial statement. Therefore, it fits best under Regulatory Filings (RNS).
2020-08-20 Chinese
关于股东Beta Pharma,Inc.仲裁申请事项的公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement from Beta Pharma, Inc. regarding an arbitration application filed with the Hong Kong International Arbitration Centre concerning a trademark transfer dispute. It details the parties involved, the arbitration requests, and the potential impact on the company's profits. The document does not contain financial statements, audit results, or detailed financial data. It is a legal proceeding update related to arbitration. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification. Hence, the classification is LTR with high confidence.
2020-08-18 Chinese
关于盐酸恩沙替尼eXalt3研究期中分析结果发布的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Betta Pharmaceuticals regarding the interim analysis results of a clinical study (eXalt3) for a new drug (Ensartinib). It provides detailed clinical trial results and future plans for drug approval and marketing. The document is short (983 characters) and is an announcement of research results rather than a financial report or regulatory filing. It does not contain financial statements, management changes, voting results, or other regulatory information. It is not a report publication announcement since it contains substantive content about the clinical trial results. The content fits best under a Regulatory Filings (RNS) category as it is a general regulatory announcement about clinical trial progress and company plans, which does not fit other specific categories.
2020-08-09 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.